Mounjaro's class of medication — and why it matters for weight loss

The biggest misconception: Mounjaro is not simply 'a GLP-1 drug'

Most people who have heard of weight-loss injections assume they all work the same way. That assumption is understandable, Mounjaro and Wegovy are both once-weekly injections, both slow gastric emptying, and both carry a similar nausea profile at the start of treatment. But the comparison stops at the mechanism.

Semaglutide (Wegovy) activates the GLP-1 receptor only. Tirzepatide activates two distinct receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a gut hormone involved in energy storage and insulin secretion. When both receptors are engaged at once, appetite signalling is suppressed through complementary pathways rather than a single one. That is why tirzepatide sits in its own pharmacological class (dual GIP/GLP-1 receptor agonist) rather than being grouped with semaglutide under the GLP-1 agonist umbrella.

The distinction is not just academic. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, adults treated with tirzepatide lost more weight on average than those treated with semaglutide 2.4 mg over 72 weeks. NICE's appraisal of tirzepatide noted that indirect comparisons from the wider evidence base also favour tirzepatide. You can read more about how tirzepatide works including the receptor biology in detail.

Understanding the class also clarifies why Mounjaro is not interchangeable with other GLP-1 medicines even if a pharmacist or GP uses the broader term loosely. It is a distinct drug in a distinct class.

What the dual-agonist class means for your body, appetite, blood sugar, and the gut

Both GLP-1 and GIP receptors are found in the brain as well as the gut. When tirzepatide binds to them, it signals a sense of fullness sooner during a meal and reduces appetite between meals. It also slows the rate at which food leaves the stomach (a pharmacological effect called delayed gastric emptying) which contributes to that fullness signal and, incidentally, to the nausea some people notice in the first few weeks.

On the blood-sugar side, both receptors are involved in insulin release. GIP in particular enhances insulin secretion after a meal in a glucose-dependent way, meaning it only acts when blood sugar is elevated, a useful safety feature. This is why Mounjaro holds a licence for type 2 diabetes as well as weight management.

The gastric-emptying effect has one practical consequence the class shares with other GLP-1 medicines: it can reduce how quickly and how completely the gut absorbs other oral medications, including oral contraceptives. The NHS specifically advises that women using the combined pill or progestogen-only pill should add a barrier method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase. Interactions with other medications, including those for ADHD, are worth discussing at your consultation, the prescriber reviews your full medicine list as a matter of course.

The formulation of tirzepatide in each Mounjaro KwikPen is a ready-to-inject solution; there is nothing to mix or prepare, which is one reason the pen format has been well received.

Where this class sits within UK licensing and NICE guidance

Mounjaro received its UK marketing authorisation for weight management from the MHRA and is a Black Triangle (▼) medicine, meaning it is subject to additional monitoring while post-marketing safety data accumulates. NICE recommended it in TA1026 (published December 2024, updated September 2025) for adults with a BMI of 35 or above who also have at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. BMI thresholds are set 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

On the NHS, access is being rolled out in phases. From June 2025, the first cohort (people with a BMI of 40 or above and four or more of those conditions) could receive it through GP practices participating in the new QOF contract. A second cohort opened in June 2026. Many people eligible on clinical grounds still face a wait, or fall slightly below the NHS thresholds; private prescribing through a regulated pharmacy is the alternative route, subject to a clinical assessment.

For a cost-context comparison, the Mounjaro price comparison page sets out how private treatment is typically priced and what any legitimate prescription should include. Treatment pricing is also confirmed on the weight-loss medication overview.

If you have been reading about patient experiences with Mounjaro and want to understand the clinical picture alongside them, our clinical team publishes evidence-based commentary on what the data actually shows.

Side effects tied to how this drug class works

Because the dual-agonist class slows gastric emptying, the most common side effects are gastrointestinal: nausea, loose stools, constipation, and indigestion, particularly after starting treatment or moving to a higher dose. For most people these settle within days to a couple of weeks as the body adjusts. The titration schedule (starting at 2.5 mg and stepping up every four weeks or so, guided by the prescriber) exists precisely to give the gut time to adapt.

Less common but more serious effects to be aware of include acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients that severe, persistent stomach pain, especially if it reaches into the back, needs urgent medical attention. That update covered GLP-1 receptor agonists as a class; tirzepatide shares the signal given its overlapping mechanism.

Injection-site reactions, fatigue, and headache are also reported, though typically mild. Anyone who suspects a side effect can report it through the Yellow Card scheme at yellowcard.mhra.gov.uk. If a holiday or a busy patch (say, orders placed at the end of the month when finances align) means a dose is delayed, the prescriber and patient information leaflet should be the first port of call, not a forum. Missed-dose decisions depend on how long the gap is and what dose you are on. Full details of the Mounjaro pen and treatment are covered in our main Mounjaro guide.

Ready to find out whether tirzepatide is clinically suitable for you? Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.